Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review

André S Pollmann, Andrea L Murphy, Joel C Bergman, David M Gardner, André S Pollmann, Andrea L Murphy, Joel C Bergman, David M Gardner

Abstract

Background: Long-term sedative use is prevalent and associated with significant morbidity, including adverse events such as falls, cognitive impairment, and sedation. The development of dependence can pose significant challenges when discontinuation is attempted as withdrawal symptoms often develop. We conducted a scoping review to map and characterize the literature and determine opportunities for future research regarding deprescribing strategies for long-term benzodiazepine and Z-drug (zopiclone, zolpidem, and zaleplon) use in community-dwelling adults.

Methods: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE, PsycINFO, CINAHL, TRIP, and JBI Ovid databases and conducted a grey literature search. Articles discussing methods for deprescribing benzodiazepines or Z-drugs in community-dwelling adults were selected.

Results: Following removal of duplicates, 2797 articles were reviewed for eligibility. Of these, 367 were retrieved for full-text assessment and 139 were subsequently included for review. Seventy-four (53%) articles were original research, predominantly randomized controlled trials (n = 52 [37%]), whereas 58 (42%) were narrative reviews and seven (5%) were guidelines. Amongst original studies, pharmacologic strategies were the most commonly studied intervention (n = 42 [57%]). Additional deprescribing strategies included psychological therapies (n = 10 [14%]), mixed interventions (n = 12 [16%]), and others (n = 10 [14%]). Behaviour change interventions were commonly combined and included enablement (n = 56 [76%]), education (n = 36 [47%]), and training (n = 29 [39%]). Gradual dose reduction was frequently a component of studies, reviews, and guidelines, but methods varied widely.

Conclusions: Approaches proposed for deprescribing benzodiazepines and Z-drugs are numerous and heterogeneous. Current research in this area using methods such as randomized trials and meta-analyses may too narrowly encompass potential strategies available to target this phenomenon. Realist synthesis methods would be well suited to understand the mechanisms by which deprescribing interventions work and why they fail.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram showing results of search and process of selecting articles for review

References

    1. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry. 2002;63:817–825. doi: 10.4088/JCP.v63n0912.
    1. Olfson M, Pincus HA. Use of benzodiazepines in the community. Arch Intern Med. 1994;154:1235–1240. doi: 10.1001/archinte.1994.00420110079009.
    1. Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry. 2005;17:189–197. doi: 10.1080/09540260500071863.
    1. Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007;16:560–570. doi: 10.1002/pds.1367.
    1. Alessi-Severini S, Boulton JM, Enns MW, Dahl M, Collins DM, Chateau D, et al. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open. 2014;2:e208–e216. doi: 10.9778/cmajo.20130076.
    1. Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry. 2005;13:892–900. doi: 10.1097/00019442-200510000-00009.
    1. Hogan DB, Maxwell CJ, Fung TS, Ebly EM. Canadian Study of Health and Aging. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian study of health and aging. Can J Clin Pharmacol. 2003;10:72–77.
    1. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174:890–898. doi: 10.1001/jamainternmed.2014.949.
    1. Cunningham CM, Hanley GE, Morgan S. Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy. 2010;97:122–129. doi: 10.1016/j.healthpol.2010.03.008.
    1. Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Begaud B, Verdoux H, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol. 2004;60:523–529. doi: 10.1007/s00228-004-0808-2.
    1. van Hulten R, Isacson D, Bakker A, Leufkens HG. Comparing patterns of long-term benzodiazepine use between a Dutch and a Swedish community. Pharmacoepidemiol Drug Saf. 2003;12:49–53. doi: 10.1002/pds.784.
    1. Patten SB, Williams JV, Lavorato DH, Kassam A, Sabapathy CD. Pharmacoepidemiology of benzodiazepine and sedative-hypnotic use in a Canadian general population cohort during 12 years of follow-up. Can J Psychiatry. 2010;55:792–799.
    1. Esposito E, Barbui C, Patten SB. Patterns of benzodiazepine use in a Canadian population sample. Epidemiol Psichiatr Soc. 2009;18:248–254.
    1. De Wilde S, Carey IM, Harris T, Richards N, Victor C, Hilton SR, et al. Trends in potentially inappropriate prescribing amongst older UK primary care patients. Pharmacoepidemiol Drug Saf. 2007;16:658–667. doi: 10.1002/pds.1306.
    1. Lai HY, Hwang SJ, Chen YC, Chen TJ, Lin MH, Chen LK. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese national health insurance program. Clin Ther. 2009;31:1859–1870. doi: 10.1016/j.clinthera.2009.08.023.
    1. Smolders M, Laurant M, van Rijswijk E, Mulder J, Braspenning J, Verhaak P, et al. The impact of co-morbidity on GPs’ pharmacological treatment decisions for patients with an anxiety disorder. Fam Pract. 2007;24:538–546. doi: 10.1093/fampra/cmm062.
    1. Ford ES, Wheaton AG, Cunningham TJ, Giles WH, Chapman DP, Croft JB. Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the national ambulatory medical care survey 1999–2010. Sleep. 2014;37:1283–1293.
    1. Olfson M, King M, Schoenbaum M. Benzodiazepine Use in the United States. JAMA Psychiatry. 2015;72:136–142. doi: 10.1001/jamapsychiatry.2014.1763.
    1. Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T, Siriwardena AN. General practitioners’ experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesis. BMC Fam Pract. 2013;14:191. doi: 10.1186/1471-2296-14-191.
    1. Martinsson G, Fagerberg I, Wiklund-Gustin L, Lindholm C. Specialist prescribing of psychotropic drugs to older persons in Sweden—register-based study of 188,024 older persons. BMC Psychiatry. 2012;12:197. doi: 10.1186/1471-244X-12-197.
    1. Everitt H, McDermott L, Leydon G, Yules H, Baldwin D, Little P. GPs’ management strategies for patients with insomnia: a survey and qualitative interview study. Br J Gen Pract. 2014;64:e112–e119. doi: 10.3399/bjgp14X677176.
    1. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30:793–807. doi: 10.1007/s40266-013-0106-8.
    1. Cook JM, Biyanova T, Masci C, Coyne JC. Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med. 2007;22:1094–1100. doi: 10.1007/s11606-007-0205-5.
    1. Frank C. Deprescribing: a new word to guide medication review. CMAJ. 2014;186:407–408. doi: 10.1503/cmaj.131568.
    1. Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003;33:323–328. doi: 10.1002/jppr2003334323.
    1. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162:225–233.
    1. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169. doi: 10.1136/bmj.38623.768588.47.
    1. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf. 2002;11:97–104. doi: 10.1002/pds.686.
    1. Wagner AK, Zhang F, Soumerai SB, Walker AM, Gurwitz JH, Glynn RJ, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004;164:1567–1572. doi: 10.1001/archinte.164.14.1567.
    1. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352:1331–1336. doi: 10.1016/S0140-6736(98)04087-2.
    1. McIntosh B, Clark M, Spry C. Benzodiazepines in older adults: a review of clinical effectiveness, cost-effectiveness, and guidelines. Canadian Agency for Drugs and Technologies in Health. 2011. . Accessed 16 Nov 2014.
    1. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. doi: 10.1186/1748-5908-5-69.
    1. Kastner M, Tricco AC, Soobiah C, Lillie E, Perrier L, Horsley T, et al. What is the most appropriate knowledge synthesis method to conduct a review? Protocol for a scoping review BMC Med Res Methodol. 2012;12:114. doi: 10.1186/1471-2288-12-114.
    1. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. doi: 10.1186/1748-5908-6-42.
    1. Arskey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32. doi: 10.1080/1364557032000119616.
    1. Valaitis R, Martin-Misener R, Wong ST, MacDonald M, Meagher-Stewart D, Austin P, et al. Methods, strategies and technologies used to conduct a scoping literature review of collaboration between primary care and public health. Prim Health Care Res Dev. 2012;13:219–236. doi: 10.1017/S1463423611000594.
    1. Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The global evidence mapping initiative: scoping research in broad topic areas. BMC Med Res Methodol. 2011;11:92. doi: 10.1186/1471-2288-11-92.
    1. Brien SE, Lorenzetti DL, Lewis S, Kennedy J, Ghali WA. Overview of a formal scoping review on health system report cards. Implement Sci. 2010;5:2. doi: 10.1186/1748-5908-5-2.
    1. Rumrill PD, Fitzgerald SM, Merchant WR. Using scoping literature reviews as a means of understanding and interpreting existing literature. Work. 2010;35:399–404.
    1. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123:A12–A13.
    1. Grey matters: a practical search tool for evidence-based medicine. Canadian Agency for Drugs and Technologies in Health. 2013. . Accessed 19 Jan 2014.
    1. Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI item bank. Agency for Healthcare Research and Quality. 2013. . Accessed 15 Mar 2014.
    1. Abelson JL, Curtis GC. Discontinuation of alprazolam after successful treatment of panic disorder: a naturalistic follow-up study. J Anxiety Disord. 1993;7:107–117. doi: 10.1016/0887-6185(93)90009-A.
    1. Ahmed M, Westra HA, Stewart SH. A self-help handout for benzodiazepine discontinuation using cognitive behavioral therapy. Cong Behav Pract. 2008;15:317–324. doi: 10.1016/j.cbpra.2007.05.003.
    1. Allain H, Le Coz F, Borderies P, Schuck S, Giclais DL, Patat A, et al. Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia. Hum Psychopharmacol. 1998;13:551–559. doi: 10.1002/(SICI)1099-1077(1998120)13:8<551::AID-HUP31>;2-V.
    1. Ashton H. The treatment of benzodiazepine dependence. Addiction. 1994;89:1535–1541. doi: 10.1111/j.1360-0443.1994.tb03755.x.
    1. Ashton CH, Rawlins MD, Tyrer SP. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry. 1990;157:232–238. doi: 10.1192/bjp.157.2.232.
    1. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Grégoire JP, Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ. 2003;169:1015–1020.
    1. Ballenger JC. Long-term pharmacologic treatment of panic disorder. J Clin Psychiatry. 1991;52(Suppl 2):18–23.
    1. Ballenger JC, Pecknold J, Rickels K, Sellers EM. Medication discontinuation in panic disorder. J Clin Psychiatry. 1993;54(Suppl 10):15–21.
    1. Bartholomew S. Benzodiazepine dependence in the elderly. J Am Acad Phys Assist. 1990;3:535–539.
    1. Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract. 1994;44:408–412.
    1. Belanger L, Belleville G, Morin C. Management of hypnotic discontinuation in chronic insomnia. Sleep Med Clin. 2009;4:583–592. doi: 10.1016/j.jsmc.2009.07.011.
    1. Belleville G, Guay C, Guay B, Morin CM. Hypnotic taper with or without self-help treatment of insomnia: a randomized clinical trial. J Consult Clin Psychol. 2007;75:325–335. doi: 10.1037/0022-006X.75.2.325.
    1. Blais D, Petit L. Benzodiazepines: dependence and a therapeutic approach to gradual withdrawal. Can Fam Physician. 1990;36:1779–1782.
    1. Bobes J, Rubio G, Teran A, Cervera G, Lopez-Gomez V, Vilardaga I, et al. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry. 2012;27:301–307. doi: 10.1016/j.eurpsy.2010.12.004.
    1. Burrows GD. Managing long-term therapy for panic disorder. J Clin Psychiatry. 1990;51(Suppl 11):9–12.
    1. Burrows GD, Norman TR, Judd FK, Marriott PF. Short-acting versus long-acting benzodiazepines: discontinuation effects in panic disorders. J Psychiatr Res. 1990;24(Suppl 2):65–72. doi: 10.1016/0022-3956(90)90037-Q.
    1. Cantopher T, Olivieri S, Cleave N, Edwards JG. Chronic benzodiazepine dependence: a comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry. 1990;156:406–411. doi: 10.1192/bjp.156.3.406.
    1. Chang F. Strategies for benzodiazepine withdrawal in seniors. Can Pharm J. 2005;138:38–40. doi: 10.1177/171516350513800804.
    1. Choy Y. Managing side effects of anxiolytics. Primary Psychiatry. 2007;14:68–76.
    1. Chung KF, Cheung RCH, Tam JWY. Long-term benzodiazepine users - characteristics, views and effectiveness of benzodiazepine reduction information leaflet. Singapore Med J. 1999;40:138–143.
    1. Cormack MA, Sinnott A. Psychological alternatives to long-term benzodiazepine use. J R Coll Gen Pract. 1983;33:279–281.
    1. Cormack MA, Sweeney KG, Hughes-Jones H, Foot GA. Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. Br J Gen Pract. 1994;44:5–8.
    1. Crouch G, Robson M, Hallstrom C. Benzodiazepine dependent patients and their psychological treatment. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:503–510. doi: 10.1016/0278-5846(88)90109-1.
    1. Davidson JR. Continuation treatment of panic disorder with high-potency benzodiazepines. J Clin Psychiatry. 1990;51(Suppl 12):31–37.
    1. Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28:7–20. doi: 10.1016/j.eurpsy.2011.11.003.
    1. Benzodiazepines: good practice guidelines for clinicians. Department of Health and Children, Ireland. 2002. . Accessed 19 Jan 2014.
    1. Drug misuse and dependence: UK guidelines on clinical management. Department of Health (England), the Scottish Government, Welsh Assembly Government, and Northern Ireland Executive. 2007. . Accessed 31 Mar 2014.
    1. Drake J. Temazepam ‘planpak’: a multicentre general practice trial in planned benzodiazepine hypnotic withdrawal. Curr Med Res Opin. 1991;12:390–393. doi: 10.1185/03007999109111509.
    1. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry. 1990;51(Suppl 1):3–10.
    1. DuPont RL. Thinking about stopping treatment for panic disorder. J Clin Psychiatry. 1990;51:38–45.
    1. DuPont RL. A practical approach to benzodiazepine discontinuation. J Psychiatr Res. 1990;24(Suppl 2):81–90. doi: 10.1016/0022-3956(90)90039-S.
    1. El-Guebaly N, Sareen J, Stein MB. Are there guidelines for the responsible prescription of benzodiazepines? Can J Psychiatry. 2010;55:709–714.
    1. Elsesser K, Sartory G, Maurer J. The efficacy of complaints management training in facilitating benzodiazepine withdrawal. Behav Res Ther. 1996;34:149–156. doi: 10.1016/0005-7967(95)00051-8.
    1. Office-based outpatient withdrawal techniques: a guide–anxiolytic/sedative/hypnotic drugs. Federation of Texas Psychiatry. 2002. . Accessed 31 Mar 2014.
    1. Fraser D, Peterkin GS, Gamsu CV, Baldwin PJ. Benzodiazepine withdrawal: a pilot comparison of three methods. Br J Clin Psychol. 1990;29:231–233. doi: 10.1111/j.2044-8260.1990.tb00875.x.
    1. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, et al. Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry. 1987;144:303–308. doi: 10.1176/ajp.144.3.303.
    1. Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159:2456–2460. doi: 10.1001/archinte.159.20.2456.
    1. Gilhooly TC, Webster MG, Poole NW, Ross S. What happens when doctors stop prescribing temazepam? Use of alternative therapies. Br J Gen Pract. 1998;48:1601–1602.
    1. Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders. GlaxoSmithKline. 2008. . Accessed 31 Mar 2014.
    1. Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74:908–919. doi: 10.1037/0022-006X.74.5.908.
    1. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26:461–470. doi: 10.1177/0269881111405360.
    1. Hallström C, Crouch G, Robson M, Shine P. The treatment of tranquilizer dependence by propranolol. Postgrad Med J. 1988;64(Suppl 2):40–44.
    1. Harangozo J, Magyar I, Faludy G. Use of benzodiazepines in psychiatry. Ther Hung. 1991;39:103–111.
    1. Hayward P, Wardle J, Higgitt A. Benzodiazepine research: current findings and practical consequences. Br J Clin Psychol. 1989;28:307–327. doi: 10.1111/j.2044-8260.1989.tb00835.x.
    1. Heather N, Bowie A, Ashton H, McAvoy B, Spencer I, Brodie J, et al. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: outcome of intervention. Addict Res Theory. 2004;12:141–154. doi: 10.1080/1606635310001634528.
    1. Higgitt AC, Lader MH, Fonagy P. Clinical management of benzodiazepine dependence. BMJ. 1985;91:688–690. doi: 10.1136/bmj.291.6497.688.
    1. Hofmann SG, Spiegel DA. Panic control treatment and its applications. J Psychother Pract Res. 1999;8:3–11.
    1. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:865–889. doi: 10.2165/00003495-200059040-00014.
    1. Hopkins DR, Sethi KB, Mucklow JC. Benzodiazepine withdrawal in general practice. J R Coll Gen Pract. 1982;32:758–762.
    1. Huston PG. Moderating benzodiazepine use in the elderly. Can Fam Phys. 1992;38:2459–2467.
    1. Jensen B. Benzodiazepine comparison chart. In: Jensen B, Regier L, editors. RxFiles Drug Comparison Charts. 9. Saskatoon: Saskatoon Health Region; 2013. p. 101.
    1. Keck PE, Jr, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol. 1992;12(Suppl 1):36S–41S. doi: 10.1097/00004714-199202001-00006.
    1. Alcohol and other drug withdrawal practice guidelines. Drug and Alcohol Clinical Advisory Service. 2009. . Accessed 31 Mar 2014.
    1. Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry. 2002;63(Suppl 14):27–33.
    1. Klein E, Colin V, Stolk J, Lenox RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry. 1994;151:1760–1766. doi: 10.1176/ajp.151.12.1760.
    1. Kunz D, Bineau S, Maman K, Milea D, Toumi M. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012;13:9–16. doi: 10.1517/14656566.2012.638284.
    1. Lader M. Benzodiazepines revisited–will we ever learn? Addiction. 2011;106:2086–2109. doi: 10.1111/j.1360-0443.2011.03563.x.
    1. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry. 1987;48(Suppl 12):12–16.
    1. Lader M, Farr I, Morton S. A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. Int Clin Psychopharmacol. 1993;8:31–36. doi: 10.1097/00004850-199300810-00005.
    1. Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol. 1987;7:11–15. doi: 10.1097/00004714-198702000-00003.
    1. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19–34. doi: 10.2165/0023210-200923010-00002.
    1. Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, et al. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomised double-blind placebo-controlled trial. Br J Clin Pharmacol. 2013;77:975–985. doi: 10.1111/bcp.12294.
    1. Landry MJ, Smith DE, McDuff DR, Baughman OL., 3rd Benzodiazepine dependence and withdrawal: identification and medical management. J Am Board Fam Pract. 1992;5:167–175.
    1. Lemoine P, Allain H, Janus C, Sutet P. Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur Psychiatry. 1995;10(3):161S–165S. doi: 10.1016/0924-9338(96)80098-8.
    1. Lemoine P, Kermadi I, Garcia-Acosta S, Garay RP, Dib M. Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:131–137. doi: 10.1016/j.pnpbp.2005.08.015.
    1. Lopez-Peig C, Mundet X, Casabella B, del Val JL, Lacasta D, Diogene E. Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain. BMC Res Notes. 2012;5:684. doi: 10.1186/1756-0500-5-684.
    1. MacKinnon GL, Parker WA. Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse. 1982;9:19–33. doi: 10.3109/00952998209002608.
    1. Insomnia: benzodiazepines, complementary medicines and non-drug treatments. National Prescribing Service. 2002. . Accessed 31 Mar 2014.
    1. Marriott S, Tyrer P. Benzodiazepine dependence: avoidance and withdrawal. Drug Saf. 1993;9:93–103. doi: 10.2165/00002018-199309020-00003.
    1. Mercier-Guyon C, Chabannes JP, Saviuc P. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Curr Med Res Opin. 2004;20:1347–1355. doi: 10.1185/030079904125004457.
    1. Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29:127–134. doi: 10.1055/s-2007-979558.
    1. Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallières A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161:332–342. doi: 10.1176/appi.ajp.161.2.332.
    1. Morin CM, Colecchi CA, Ling WD, Sood RK. Cognitive behavior therapy to facilitate benzodiazepine discontinuation among hypnotic-dependent patients with insomnia. Behav Ther. 1995;26:733–745. doi: 10.1016/S0005-7894(05)80042-5.
    1. Morton S, Lader M. Buspirone treatment as an aid to benzodiazepine withdrawal. J Psychopharmacol. 1995;9:331–335. doi: 10.1177/026988119500900407.
    1. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract. 2011;61:e573–e578. doi: 10.3399/bjgp11X593857.
    1. Murphy SM, Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry. 1991;158:511–516. doi: 10.1192/bjp.158.4.511.
    1. Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci. 2006;60:605–610. doi: 10.1111/j.1440-1819.2006.01565.x.
    1. Nardi AE, Freire RC, Valenca AM, Amrein R, de Cerqueira AC, Lopes FL, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010;30:290–293. doi: 10.1097/JCP.0b013e3181dcb2f3.
    1. Nathan RG, Robinson D, Cherek DR, Sebastian CS, Hack M, Davison S. Alternative treatments for withdrawing the long-term benzodiazepine user: a pilot study. Int J Addict. 1986;21:195–211. doi: 10.3109/10826088609063450.
    1. Management options for improving sleep. National Prescribing Service. 2010. . Accessed 31 Mar 2014.
    1. Benzodiazepines: managing withdrawal. National Prescribing Service. 1999. . Accessed 31 Mar 2014.
    1. Benzodiazepine and z-drug withdrawal. National Health Service. 2013. . Accessed 31 Mar 2014.
    1. What’s wrong with prescribing hypnotics? Drug Ther Bull.() 2004;42:89–93.
    1. Appendix B-6: Benzodiazepine tapering. In: Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. National Opioid Use Guideline Group. 2010. . Accessed 31 Mar 2014.
    1. Noyes R, Jr, Garvey MJ, Cook BL, Perry PJ. Benzodiazepine withdrawal: a review of the evidence. J Clin Psychiatry. 1988;49:382–389.
    1. Drug and alcohol withdrawal clinical practice guidelines. NSW Government. 2008. . Accessed 31 Mar 2014.
    1. O’Connor K, Marchand A, Brousseau L, Aardema F, Mainguy N, Landry P, et al. Cognitive-behavioural, pharmacological and psychosocial predictors of outcome during tapered discontinuation of benzodiazepine. Clin Psychol Psychother. 2008;15:1–14. doi: 10.1002/cpp.556.
    1. Onyett SR. The benzodiazepine withdrawal syndrome and its management. J R Coll Gen Pract. 1989;39:160–163.
    1. Onyett SR, Turpin G. Benzodiazepine withdrawal in primary care: a comparison of behavioural group training and individual sessions. Behav Psychother. 1988;16:297–312. doi: 10.1017/S0141347300014154.
    1. Otto MW, Hong JJ, Safren SA. Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavior therapy. Curr Pharm Des. 2002;8:75–80. doi: 10.2174/1381612023396726.
    1. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010;48:720–727. doi: 10.1016/j.brat.2010.04.002.
    1. Otto MW, Pollack MH, Meltzer-Brody S, Rosenbaum JF. Cognitive-behavioral therapy for benzodiazepine discontinuation in panic disorder patients. Psychopharmacol Bull. 1992;28:123–130.
    1. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry. 1993;150:1485–1490. doi: 10.1176/ajp.150.10.1485.
    1. Oude Voshaar RC, Couvee JE, Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213–220. doi: 10.1192/bjp.189.3.213.
    1. Oude Voshaar RC, Gorgels WJ, Mol AJ, Balkom AJ, Lisdonk EH, Breteler MH, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182:498–504. doi: 10.1192/bjp.182.6.498.
    1. Parr JM, Kavanagh DJ, Cahill L, Mitchell G, Young RM. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104:13–24. doi: 10.1111/j.1360-0443.2008.02364.x.
    1. Pat-Horenczyk R, Hacohen D, Herer P, Lavie P. The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology (Berl) 1998;140:450–457. doi: 10.1007/s002130050789.
    1. Pecknold JC. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res. 1993;27(Suppl 1):155–170. doi: 10.1016/0022-3956(93)90025-W.
    1. Peles E, Hetzroni T, Bar-Hamburger R, Adelson M, Schreiber S. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction. 2007;102:1947–1953. doi: 10.1111/j.1360-0443.2007.02007.x.
    1. Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D. Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg. 2003;58:27–36. doi: 10.1179/acb.2003.58.1.004.
    1. Poyares DR, Guilleminault C, Ohayon MM, Tufik S. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:539–545. doi: 10.1016/S0278-5846(01)00305-0.
    1. Raju B, Meagher D. Patient-controlled benzodiazepine dose reduction in a community mental health service. Ir J Psychol Med. 2005;22:42–45. doi: 10.1017/S0790966700008909.
    1. Rickels K, DeMartinis N, García-España F, Greenblatt DJ, Mandos LA, Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry. 2000;157:1973–1979. doi: 10.1176/appi.ajp.157.12.1973.
    1. Rickels K, Schweizer E, García-España F, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 1999;141:1–5. doi: 10.1007/s002130050798.
    1. Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19(Suppl 2):12S–16S. doi: 10.1097/00004714-199912002-00003.
    1. Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharmacol. 1998;18:121–131. doi: 10.1097/00004714-199804000-00004.
    1. Roth SM. Anxiety disorders and the use and abuse of drugs. J Clin Psychiatry. 1989;50(Suppl 11):30–35.
    1. Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK. Adjunctive treatment of benzodiazepine discontinuation syndromes: a review. J Psychiatr Res. 1993;27(Suppl 1):143–153. doi: 10.1016/0022-3956(93)90024-V.
    1. Roy-Byrne PP, Cowley DS. The use of benzodiazepines in the workplace. J Psychoactive Drugs. 1990;22:461–465. doi: 10.1080/02791072.1990.10472220.
    1. Roy-Byrne PP, Hommer D. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med. 1988;84:1041–1052. doi: 10.1016/0002-9343(88)90309-9.
    1. Rynn M, García-España F, Greenblatt DJ, Mandos LA, Schweizer E, Rickels K. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. J Clin Psychopharmacol. 2003;23:505–508. doi: 10.1097/01.jcp.0000088907.24613.3f.
    1. Sanchez-Craig M, Cappell H, Busto U, Kay G. Cognitive-behavioural treatment for benzodiazepine dependence: a comparison of gradual versus abrupt cessation of drug intake. Br J Addict. 1987;82:1317–1327. doi: 10.1111/j.1360-0443.1987.tb00434.x.
    1. Saul PA, Korlipara K, Presley P. A randomised, multicentre, double-blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Ther. 1989;15:117–123.
    1. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl. 1998;393:95–101. doi: 10.1111/j.1600-0447.1998.tb05973.x.
    1. Schweizer E, Rickels K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry. 1986;143:1590–1592. doi: 10.1176/ajp.143.12.1590.
    1. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48:448–452. doi: 10.1001/archpsyc.1991.01810290060012.
    1. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines II: effects of gradual taper. Arch Gen Psychiatry. 1990;47:908–915. doi: 10.1001/archpsyc.1990.01810220024003.
    1. Schweizer E, Case WG, García-España F, Greenblatt DJ, Rickels K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology (Berl) 1995;117:424–429. doi: 10.1007/BF02246214.
    1. Shapiro CM, Sherman D, Peck DF. Withdrawal from benzodiazepines by initially switching to zopiclone. Eur Psychiatry. 1995;10(Suppl 3):145S–151S. doi: 10.1016/0924-9338(96)80096-4.
    1. Sloan E. Medication and substance use: keeping insomnia treatment safe. Insomnia Rounds. 2013;2:1–6.
    1. Smith AJ, Tett SE. Improving the use of benzodiazepines–is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res. 2010;10:321. doi: 10.1186/1472-6963-10-321.
    1. Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19(Suppl 2):17S–22S. doi: 10.1097/00004714-199912002-00004.
    1. Stewart R, Niessen WJ, Broer J, Snijders TA, Haaijer-Ruskamp FM, Meyboom-De JB. General practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application. J Clin Epidemiol. 2007;60:1076–1084. doi: 10.1016/j.jclinepi.2006.11.024.
    1. Taylor DJ, Schmidt-Nowara W, Jessop CA, Ahearn J. Sleep restriction therapy and hypnotic withdrawal versus sleep hygiene education in hypnotic using patients with insomnia. J Clin Sleep Med. 2010;6:169–175.
    1. Management of anxiety disorders in primary care. Therapeutics Initiative. 1997. . Accessed 31 Mar 2014.
    1. Thirtala T, Kaur K, Karlapati SK, Lippmann S. Consider this slow-taper program for benzodiazepines. Curr Psychiatr. 2013;12:55–56.
    1. Addressing hypnotic medicines use in primary care. National Prescribing Service. 2010. . Accessed 31 Mar 2014.
    1. Tyrer P, Ferguson B, Hallström C, Michie M, Tyrer S, Cooper S, et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry. 1996;168:457–461. doi: 10.1192/bjp.168.4.457.
    1. Tyrer PJ, Seivewright N. Identification and management of benzodiazepine dependence. Postgrad Med J. 1984;60(Suppl 2):41–46.
    1. Udelman HD, Udelman DL. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry. 1990;51:46–50.
    1. van de Steeg-van Gompel CH, Wensing M, De Smet PA. Implementation of a discontinuation letter to reduce long-term benzodiazepine use: a cluster randomized trial. Drug Alcohol Depend. 2009;99:105–114. doi: 10.1016/j.drugalcdep.2008.07.009.
    1. Vicens C, Fiol F, Llobera J, Campoamor F, Mateu C, Alegret S, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract. 2006;56:958–963.
    1. Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socías I, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204:471–479. doi: 10.1192/bjp.bp.113.134650.
    1. Vissers FH, Knipschild PG, Crebolder HF. Is melatonin helpful in stopping the long-term use of hypnotics? a discontinuation trial. Pharm World Sci. 2007;29:641–646. doi: 10.1007/s11096-007-9118-y.
    1. Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches. Addiction. 2002;97:851–859. doi: 10.1046/j.1360-0443.2002.00129.x.
    1. Woodward M. Hypnotics: options to help your patients stop. Aust Fam Physician. 2000;29:939–944.
    1. Woodward M. Hypnosedatives in the elderly: a guide to appropriate use. CNS Drugs. 1999;11:263–279. doi: 10.2165/00023210-199911040-00003.
    1. Zee P, Wang-Weigand S, Roth T. Facilitation of zolpidem discontinuation using ramelteon in subjects with chronic insomnia. Am J Addict. 2011;20:380–381.
    1. Atkins D, Best D, Briss PA, Mrukowicz J, O’Connell D, Oxman AD, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. doi: 10.1136/bmj.328.7454.1490.
    1. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, et al. Users’ Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290–1296. doi: 10.1001/jama.284.10.1290.
    1. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users’ Guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA. 1995;274:1800–1804. doi: 10.1001/jama.1995.03530220066035.
    1. Oxford levels of evidence 2. Centre for Evidence Based Medicine. 2011. . Accessed 28 Nov 2014.
    1. Coumou HC, Meijman FJ. How do primary care physicians seek answers to clinical questions? A literature review. J Med Libr Assoc. 2006;94:55–60.
    1. Lewis PJ, Tully MP. The discomfort of an evidence-based prescribing decision. J Eval Clin Pract. 2009;15:1152–1158. doi: 10.1111/j.1365-2753.2009.01250.x.
    1. Swennen MH, van der Heijden GJ, Boeije HR, van Rheenen N, Verheul FJ, van der Graaf Y, et al. Doctors’ perceptions and use of evidence-based medicine: a systematic review and thematic synthesis of qualitative studies. Acad Med. 2013;88:1384–1396. doi: 10.1097/ACM.0b013e31829ed3cc.
    1. Murphy AL, Fleming M, Martin-Misener R, Sketris IS, MacCara M, Gass D. Drug information resources used by nurse practitioners and collaborating physicians at the point of care in Nova Scotia. Canada: a survey and review of the literature BMC Nurs. 2006;5:5.
    1. Kravitz RL, Bell RA. Media, messages, and medication: strategies to reconcile what patients hear, what they want, and what they need from medications. BMC Med Inform Decis Mak. 2013;13(Suppl 3):S5. doi: 10.1186/1472-6947-13-S3-S5.
    1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. doi: 10.1136/bmj.g1687.
    1. Albrecht L, Archibald M, Arseneau D, Scott SD. Development of a checklist to assess the quality of reporting of knowledge translation interventions using the workgroup for intervention development and evaluation research (WIDER) recommendations. Implement Sci. 2013;8:52. doi: 10.1186/1748-5908-8-52.
    1. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. doi: 10.1186/1748-5908-4-50.
    1. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2:E225–E232. doi: 10.9778/cmajo.20140009.
    1. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review–a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005;10:21–34. doi: 10.1258/1355819054308530.
    1. Rycroft-Malone J, McCormack B, Hutchinson AM, DeCorby K, Bucknall TK, Kent B, et al. Realist synthesis: illustrating the method for implementation research. Implement Sci. 2012;7:33. doi: 10.1186/1748-5908-7-33.
    1. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78:738–747. doi: 10.1111/bcp.12386.
    1. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust. 2014;201:386–389. doi: 10.5694/mja13.00200.
    1. Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33:1223–1237. doi: 10.1017/S0033291703008213.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir